医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Technavio Says High Prevalence of Autoimmune Disorders Will Drive Growth in the Global SLE Drugs Market Through 2019

2015年04月23日 PM11:05
このエントリーをはてなブックマークに追加


 

LONDON

According to a new report from research firm Technavio, the global SLE drugs market is expected to grow at a CAGR of 22.41% from 2015-2019.

About the Report

SLE, or lupus, is a chronic autoimmune disease where the immune system attacks and destroys healthy tissues in the body, including the skin, heart, lungs, kidneys, joints, and nervous system.

An increase in the prevalence of this and other autoimmune disorders is expected to contribute to growth in the SLE drugs market.

“Growing prevalence of autoimmune disease has led to the introduction of favorable government initiatives like the Affordable Care Act,” says Faisal Ghaus, Vice President of Technavio.

According to the latest report by Technavio, knowledge about the diagnosis of Systemic Lupus Erythematosus (SLE) and its treatment is growing in Europe and Asia—areas where the disease is more prevalent. Additionally, numerous public campaigns aimed at increasing awareness levels are also being conducted.

“The Lupus Foundation of America has been implementing various projects to increase federal support for lupus research and services for assisting people and families affected by it,” says Ghaus.

Market Scope and Calculation of Market Size

This report covers the present scenario and the growth prospects of the global SLE drugs market from 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of SLE.

Key Information Covered in the Report:

  • Key Vendors:

    • BMS Co.
    • GSK plc
    • ImmuPharma plc
    • Merck Serono SA
    • UCB SA
  • Market Growth Drivers:
    • High prevalence of autoimmune diseases
    • For a full detailed list, view our report.
  • Market Challenges:
  • Market Trends:

Technavio currently has more than 3000 market research reports on a huge range of topics, including 200+ reports on the drugs market:

If you are interested in more information, please contact our media team at media@technavio.com.

CONTACT

Technavio Research
Jes Ellacott
US: +1 630 333 9501
UK:
+44 208 123 1770
Media & Marketing Executive
www.technavio.com
media@technavio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent